miR- 26a Sensitizes Melanoma Cells To Dabrafenib Via Targeting HMGB1-Dependent Autophagy Pathways

References

• Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012;26:1131–1155. doi:10.1101/gad.191999.11222661227
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Marincola FM. 2015: the year of anti-PD-1/PD-L1s against melanoma and beyond. EBioMedicine. 2015;2:92–93. doi:10.1016/j.ebiom.2015.01.01126137543
   PubMed Web of Science ®Google Scholar
• Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol. 2014;15:e371–e381. doi:10.1016/S1470-2045(14)70072-525079100
   PubMed Web of Science ®Google Scholar
• Simeone E, Grimaldi AM, Ascierto PA. Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. Melanoma Manag. 2015;2:41–50. doi:10.2217/mmt.14.3030190830
   PubMedGoogle Scholar
• Korn EL, Liu P-Y, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527–534. doi:10.1200/JCO.2007.12.783718235113
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–819. doi:10.1056/NEJMoa100201120818844
   PubMed Web of Science ®Google Scholar
• Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526:583–586. doi:10.1038/nature1498226466569
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516. doi:10.1056/NEJMoa110378221639808
   PubMed Web of Science ®Google Scholar
• Lo RS. Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas. Pharmacogenomics. 2012;13:125–128. doi:10.2217/pgs.11.16622256862
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2011;2:336–346. doi:10.18632/oncotarget.26221505228
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–866. doi:10.1038/nrc199717060945
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–469. doi:10.1016/j.molmed.2014.06.00525027972
   PubMed Web of Science ®Google Scholar
• Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6:590–610. doi:10.1016/j.molonc.2012.09.00623102669
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004. doi:10.1073/pnas.030732310114973191
   PubMed Web of Science ®Google Scholar
• Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer – a brief overview. Adv Biol Regul. 2015;57:1–9. doi:10.1016/j.jbior.2014.09.01325294678
   PubMedGoogle Scholar
• Jin F, Wang Y, Li M, et al. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis. 2017;8:e2540. doi:10.1038/cddis.2016.46128079894
   PubMed Web of Science ®Google Scholar
• Lin G, Liu B, Meng Z, et al. MiR-26a enhances invasive capacity by suppressing GSK3β in human lung cancer cells. Exp Cell Res. 2017;352:364–374. doi:10.1016/j.yexcr.2017.02.03328237093
   PubMed Web of Science ®Google Scholar
• Zhao WT, Lin X-L, Liu Y, et al. miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2. Lab Invest. 2019;99:1484–1500. doi:10.1038/s41374-019-0270-531201367
   PubMed Web of Science ®Google Scholar
• Coronel-Hernández J, López-Urrutia E, Contreras-Romero C, et al. Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN-AKT axis. Cancer Cell Int. 2019;19:80. doi:10.1186/s12935-019-0802-530983885
   PubMed Web of Science ®Google Scholar
• Luzi E, Marini F, Sala SC, Tognarini I, Galli G, Brandi ML. Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res. 2008;23:287–295. doi:10.1359/jbmr.07101118197755
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev. 2012;249:158–175. doi:10.1111/j.1600-065X.2012.01146.x22889221
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Lippincott-Schwartz J, Yin X-M, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17:654–666. doi:10.1158/1078-0432.CCR-10-263421325294
   PubMed Web of Science ®Google Scholar
• Gong T, Yu Y, Yang B, et al. Celecoxib suppresses cutaneous squamous-cell carcinoma cell migration via inhibition of SDF1-induced endocytosis of CXCR4. Onco Targets Ther. 2018;11:8063–8071. doi:10.2147/OTT.S18047230519048
   PubMed Web of Science ®Google Scholar
• Ji C, Yang B, Huang SY, Huang JW, Cheng B. Salubrinal protects human skin fibroblasts against UVB-induced cell death by blocking endoplasmic reticulum (ER) stress and regulating calcium homeostasis. Biochem Biophys Res Commun. 2017;493:1371–1376. doi:10.1016/j.bbrc.2017.10.01228988108
   PubMed Web of Science ®Google Scholar
• Ghanbari R, Mosakhani N, Asadi J, et al. Downregulation of plasma MiR-142-3p and MiR-26a-5p in patients with colorectal carcinoma. Iran J Cancer Prev. 2015;8:e2329. doi:10.17795/ijcp232926413249
   PubMedGoogle Scholar
• Song Q, Xu K. [MicroRNA-26a and tumor]. Zhongguo Fei Ai Za Zhi. 2017;20:769–774. doi:10.3779/j.issn.1009-3419.2017.11.0829167007
   PubMedGoogle Scholar
• Lopez-Urrutia E, Coronel-Hernández J, García-Castillo V, et al. MiR-26a downregulates retinoblastoma in colorectal cancer. Tumour Biol. 2017;39:1010428317695945. doi:10.1177/101042831769594528443472
   PubMed Web of Science ®Google Scholar
• Wu Z, Lu B, Li X, et al. MicroRNA-26a inhibits proliferation and tumorigenesis via targeting CKS2 in laryngeal squamous cell carcinoma. Clin Exp Pharmacol Physiol. 2018;45:444–451. doi:10.1111/1440-1681.1289029143362
   PubMed Web of Science ®Google Scholar
• Konishi H, Fujiya M, Ueno N, et al. microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA. Biochem Biophys Res Commun. 2015;467:847–852. doi:10.1016/j.bbrc.2015.10.05526494299
   PubMed Web of Science ®Google Scholar
• Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137:1005–1017. doi:10.1016/j.cell.2009.04.02119524505
   PubMed Web of Science ®Google Scholar
• Clague J, Lippman SM, Yang H, et al. Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog. 2010;49:183–189. doi:10.1002/mc.2058819851984
   PubMed Web of Science ®Google Scholar
• Boni V, Zarate R, Villa JC, et al. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J. 2011;11:429–436. doi:10.1038/tpj.2010.5820585341
   PubMed Web of Science ®Google Scholar
• Lu J, He M-L, Wang L, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011;71:225–233. doi:10.1158/0008-5472.CAN-10-185021199804
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu -X-X, He J-R, et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 2011;32:2–9. doi:10.1093/carcin/bgq20920952513
   PubMed Web of Science ®Google Scholar
• Reuland SN, Smith SM, Bemis LT, et al. MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol. 2013;133:1286–1293. doi:10.1038/jid.2012.40023190898
   PubMed Web of Science ®Google Scholar
• Tormo E, Adam-Artigues A, Ballester S, et al. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Sci Rep. 2017;7:41309. doi:10.1038/srep4130928120942
   PubMed Web of Science ®Google Scholar
• Xu S, Wang T, Yang Z, et al. miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13. Oncotarget. 2016;7:45687–45701. doi:10.18632/oncotarget.992027285768
   PubMedGoogle Scholar
• Wen L, Cheng F, Zhou Y, Yin C. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J Gastroenterol. 2015;21:313–319. doi:10.4103/1319-3767.16620626458859
   PubMed Web of Science ®Google Scholar
• Zhang M, Duan W, Sun W. LncRNA SNHG6 promotes the migration, invasion, and epithelial–mesenchymal transition of colorectal cancer cells by miR-26a/EZH2 axis. Onco Targets Ther. 2019;12:3349–3360. doi:10.2147/OTT.S19743331118686
   PubMed Web of Science ®Google Scholar
• Zhang T, Qian H, Hu C, et al. MiR-26a mediates ultraviolet B-induced apoptosis by targeting histone methyltransferase EZH2 depending on Myc expression. Cell Physiol Biochem. 2017;43:1188–1197. doi:10.1159/00048175928977801
   PubMedGoogle Scholar
• Yao L, Lv X, Wang X. MicroRNA 26a inhibits HMGB1 expression and attenuates cardiac ischemia-reperfusion injury. J Pharmacol Sci. 2016;131:6–12. doi:10.1016/j.jphs.2015.07.02326320674
   PubMed Web of Science ®Google Scholar
• Jia P, Wu N, Jia D, Sun Y. Downregulation of MALAT1 alleviates saturated fatty acid-induced myocardial inflammatory injury via the miR-26a/HMGB1/TLR4/NF-κB axis. Diabetes Metab Syndr Obes. 2019;12:655–665. doi:10.2147/DMSO.S20315131123414
   PubMed Web of Science ®Google Scholar
• Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069–1075. doi:10.1038/nature0663918305538
   PubMed Web of Science ®Google Scholar
• Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40:280–293. doi:10.1016/j.molcel.2010.09.02320965422
   PubMed Web of Science ®Google Scholar